Autophagy in Hematological Malignancies
Metadatos
Mostrar el registro completo del ítemAutor
García Ruiz, Olga; Sánchez Maldonado, José Manuel; López Nevot, Miguel Ángel; García, Paloma; Hernández Mohedo, Francisca; González Sierra, Pedro Antonio; Martínez Bueno, Manuel; Pérez, Eva; Reyes Zurita, Fernando Jesús; Jurado Chacón, Manuel; Sáinz Pérez, JuanEditorial
MDPI
Materia
Autophagy Hematological malignancies Hematopoiesis Therapeutic target Autophagy-related variants Clinical outcomes Disease progression Patient survival
Fecha
2022-10-17Referencia bibliográfica
García Ruiz, O... [et al.]. Autophagy in Hematological Malignancies. Cancers 2022, 14, 5072. [https://doi.org/10.3390/cancers14205072]
Resumen
Autophagy is a highly conserved metabolic pathway via which unwanted intracellular
materials, such as unfolded proteins or damaged organelles, are digested. It is activated in response to
conditions of oxidative stress or starvation, and is essential for the maintenance of cellular homeostasis
and other vital functions, such as differentiation, cell death, and the cell cycle. Therefore, autophagy
plays an important role in the initiation and progression of tumors, including hematological malignancies,
where damaged autophagy during hematopoiesis can cause malignant transformation and
increase cell proliferation. Over the last decade, the importance of autophagy in response to standard
pharmacological treatment of hematological tumors has been observed, revealing completely
opposite roles depending on the tumor type and stage. Thus, autophagy can promote tumor survival
by attenuating the cellular damage caused by drugs and/or stabilizing oncogenic proteins, but can
also have an antitumoral effect due to autophagic cell death. Therefore, autophagy-based strategies
must depend on the context to create specific and safe combination therapies that could contribute
to improved clinical outcomes. In this review, we describe the process of autophagy and its role on
hematopoiesis, and we highlight recent research investigating its role as a potential therapeutic target
in hematological malignancies. The findings suggest that genetic variants within autophagy-related
genes modulate the risk of developing hemopathies, as well as patient survival.